Amphastar Will Receive $59.9m In Momenta/Sandoz Settlement
The small generics company has talked about using the cash windfall from the expected settlement to fund clinical trials and possibly M&A.
You may also be interested in...
Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.
Momenta and Sandoz must hand over $120m between them to a range of enoxaparin purchasers following final approval of a settlement agreement resolving claims the pair unfairly conspired to block further generic competition in the US to Sanofi’s Lovenox blood-thinner.
Long-running US patent and antitrust litigation between Sandoz, Momenta and Amphastar over enoxaparin has been brought to an end after the parties agreed a settlement deal.